OraSure Technologies (OSUR) Downgraded by Zacks Investment Research

OraSure Technologies (NASDAQ:OSUR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. “

OSUR has been the topic of several other research reports. ValuEngine downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. BidaskClub upgraded shares of OraSure Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 20th. Jefferies Group downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Finally, Canaccord Genuity restated a “buy” rating and set a $24.00 price objective on shares of OraSure Technologies in a report on Friday, February 2nd. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $22.25.

OraSure Technologies (NASDAQ OSUR) opened at $17.46 on Tuesday. OraSure Technologies has a fifty-two week low of $10.28 and a fifty-two week high of $23.01. The stock has a market cap of $1,091.67, a PE ratio of 35.29, a PEG ratio of 4.60 and a beta of 1.43.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.01. OraSure Technologies had a net margin of 18.52% and a return on equity of 13.09%. The firm had revenue of $52.00 million for the quarter, compared to the consensus estimate of $50.20 million. During the same quarter in the prior year, the company posted $0.13 earnings per share. The company’s revenue for the quarter was up 46.5% compared to the same quarter last year. research analysts forecast that OraSure Technologies will post 0.31 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of OSUR. New York State Common Retirement Fund increased its holdings in OraSure Technologies by 20.2% in the 2nd quarter. New York State Common Retirement Fund now owns 61,800 shares of the medical instruments supplier’s stock worth $1,067,000 after buying an additional 10,399 shares during the period. Northern Trust Corp increased its holdings in OraSure Technologies by 6.0% in the 2nd quarter. Northern Trust Corp now owns 761,667 shares of the medical instruments supplier’s stock worth $13,146,000 after buying an additional 43,407 shares during the period. Vanguard Group Inc. increased its holdings in OraSure Technologies by 19.8% in the 2nd quarter. Vanguard Group Inc. now owns 5,352,832 shares of the medical instruments supplier’s stock worth $92,390,000 after buying an additional 886,333 shares during the period. California Public Employees Retirement System increased its holdings in OraSure Technologies by 14.0% in the 2nd quarter. California Public Employees Retirement System now owns 149,400 shares of the medical instruments supplier’s stock worth $2,579,000 after buying an additional 18,400 shares during the period. Finally, Teachers Retirement System of The State of Kentucky increased its holdings in OraSure Technologies by 24.4% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 19,400 shares of the medical instruments supplier’s stock worth $335,000 after buying an additional 3,800 shares during the period. Institutional investors own 91.62% of the company’s stock.

WARNING: “OraSure Technologies (OSUR) Downgraded by Zacks Investment Research” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/02/13/orasure-technologies-osur-downgraded-by-zacks-investment-research.html.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply